Chimerix Stock

Chimerix EV/EBIT

Delisted·Apr 17, 2025

The EV/EBIT (Enterprise Value to EBIT) of Chimerix (CMRX) as of Aug 26, 2026 is -8.30. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -8.61 — a change of -3.63% (higher).

EV/EBIT

-8.30

YoY

-3.63%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Chimerix is 2026 -8.30 . EV/EBIT (Enterprise Value to EBIT) of Chimerix was 2025 -8.61 . It decreases by -3.63% higher compared to the previous year.

The Chimerix EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
59.15 USD
Jan 1, 2020
-18.00 USD
Jan 1, 2021
-4.62 USD
Jan 1, 2022
-13.27 USD
Jan 1, 2023
-8.61 USD
Jan 1, 2024
-8.30 USD
Jan 1, 2025 (e)
-138.69 USD
Jan 1, 2026 (e)
-11.80 USD
The Chimerix EV/EBIT history
YEAREV/EBITYoY
est-11.80-91.49%
est-138.69+1,571.85%
-8.30-3.63%
-8.61-35.11%
-13.27+187.15%
-4.62-74.33%
-18.00-130.42%
59.15-628.72%
-11.19+0.69%
-11.11+8.11%
-10.28+51.70%
-6.77-50.22%
-13.61
Access this data via the Eulerpool API

Chimerix Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Chimerix's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Chimerix's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Chimerix's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Chimerix grows earnings faster than its peers.

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chimerix stock

EV/EBIT (Enterprise Value to EBIT) of Chimerix is -8.30 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Chimerix changed from -8.61 to -8.30, representing a -3.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Chimerix since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Chimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Chimerix

All Key Metrics — Chimerix